Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy, Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human), 10% (GAMMAGARD LIQUID/KIOVIG) Administered Intravenously or Subcutaneously Following Administration of Recombinant Human Hyaluronidase (rHuPH20) in Subjects With Primary Immunodeficiency Diseases

NCT00814320 is registered in ClinicalTrials.gov with Baxalta now part of Shire as lead sponsor.

NCT NCT00814320
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00814320 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy, Tolerability and Pharmacokinetic Comparison of Immune Globulin Intravenous (Human), 10% (GAMMAGARD LIQUID/KIOVIG) Administered Intravenously or Subcutaneously Following Administration of Recombinant Human Hyaluronidase (rHuPH20) in Subjects With Primary Immunodeficiency Diseases
Lead sponsor
Baxalta now part of Shire
Phase
Phase 3
Overall status
Completed
Start date
December 18, 2008
Completion date
November 11, 2010
Enrollment
89 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

primary immunodeficiency diseases (pid)